OOIR: Observatory of International Research

Papers

(The H4-Index of Neurology is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Global Epidemiology of Stroke and Access to Acute Ischemic Stroke Interventions	441
International Consensus Guidance for Management of Myasthenia Gravis	323
Global prevalence and burden of HIV-associated neurocognitive disorder	199
A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City	183
National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome	180
Frequency of Neurologic Manifestations in COVID-19	174
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis	168
Incidence and Prevalence of Drug-Resistant Epilepsy	167
Global, Regional, and National Burden of Ischemic Stroke, 1990–2019	165
Worldwide Incidence and Prevalence of Neuromyelitis Optica	141
Neurologic Adverse Events of Immune Checkpoint Inhibitors	137
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies	133
Secondary Progressive Multiple Sclerosis	131
APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies	125
Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease	116
Brain arteriovenous malformations	112
Association of MRI Indices of Glymphatic System With Amyloid Deposition and Cognition in Mild Cognitive Impairment and Alzheimer Disease	110
Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke	108
Long-term safety, tolerability, and efficacy of fremanezumab in migraine	108
Natural History, Phenotypic Spectrum, and Discriminative Features of Multisystemic RFC1 Disease	105
CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms	101
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis	99
Stroke risk, phenotypes, and death in COVID-19	98
Probiotics for Constipation in Parkinson Disease	98
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques	95

Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders	92
Global Impact of COVID-19 on Stroke Care and IV Thrombolysis	91
Long-term Effect of Regular Physical Activity and Exercise Habits in Patients With Early Parkinson Disease	89
The Economic Burden of Multiple Sclerosis in the United States	88
Life Expectancy in Duchenne Muscular Dystrophy	88
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis	87
Loss of smell in patients with COVID-19	86
Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease	85
Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs	84
Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age	82
Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial	82
Sex differences in the association between major risk factors and the risk of stroke in the UK Biobank cohort study	82
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality	82
Long-term Outcomes (15 Years) After Subthalamic Nucleus Deep Brain Stimulation in Patients With Parkinson Disease	82
Astrocyte Biomarkers in Alzheimer Disease	81
Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary	81
Population-Based Prevalence of Myotonic Dystrophy Type 1 Using Genetic Analysis of Statewide Blood Screening Program	81
Associations of Social Isolation and Loneliness With Later Dementia	79
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary	78
Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET	78
Global Burden, Risk Factor Analysis, and Prediction Study of Ischemic Stroke, 1990–2030	78
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light	78
In Vivo Diagnosis of Synucleinopathies	77
Glial Fibrillary Acidic Protein Autoimmunity	75
Spontaneous ARIA-like Events in Cerebral Amyloid Angiopathy–Related Inflammation	75
Neurologic Syndromes Predict Higher In-Hospital Mortality in COVID-19	74
Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19	73
Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays	71
Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis	70
Diabetes Mellitus, Glycemic Traits, and Cerebrovascular Disease	69
Indications for Mechanical Thrombectomy for Acute Ischemic Stroke	68
Identification of GGC repeat expansion in the NOTCH2NLC gene in amyotrophic lateral sclerosis	66
Association of Collateral Status and Ischemic Core Growth in Patients With Acute Ischemic Stroke	66
Association of Metabolic Syndrome and Its Components With Risk of Stroke Recurrence and Mortality	66
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis	66
Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies	66
Applying Propensity Score Methods in Clinical Research in Neurology	65
Timing and Impact of Psychiatric, Cognitive, and Motor Abnormalities in Huntington Disease	65
β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies	65
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies	64
Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder	64
The Ictal Signature of Thalamus and Basal Ganglia in Focal Epilepsy	64
Association of Dilated Perivascular Spaces With Cognitive Decline and Incident Dementia	64